Literature DB >> 12610807

Cardiovascular risk factor screening in systemic lupus erythematosus.

Adeeba Al-Herz1, Stephanie Ensworth, Kamran Shojania, John M Esdaile.   

Abstract

OBJECTIVE: To evaluate the frequency of cardiovascular (CV) disease risk factor screening in systemic lupus erythematosus (SLE).
METHODS: Medical records of patients from a lupus clinic and 5 private practices were assessed for CV disease risk factors, including hyperlipidemia, hypertension, diabetes mellitus, smoking, family history of CV disease, antiphospholipid antibodies, hyperhomocysteinemia, postmenopausal status, obesity, and nephrotic syndrome.
RESULTS: A total of 183 records were included: 60 (33%) from the lupus clinic and 123 (67%) from private practices. Serum lipid profiles were measured in 56/183 (31%): 37/60 (62%) in the lupus clinic vs 19/123 (15%) private practice. Of the 56 with lipids measured, the individual tests obtained were as follows: total cholesterol in 56 (100%), HDL in 50 (89%), triglycerides in 49 (88%), LDL in 48 (86%), and VLDL in 33 (59%). Thirty-one of 56 patients (55%) had elevated lipids. Only 9/25 (36%) with hyperlipidemia who had a subsequent visit had a response to the hyperlipidemia charted. Of 9 nonlipid risk factors, a median of 8 were assessed in the lupus clinic vs 3 in private practices. The most frequent risk factors screened were nephrotic syndrome (91%), hypertension (74%), and smoking (59%).
CONCLUSION: Despite an inordinately high risk of CV disease in SLE, assessment of CV risk factors was surprisingly uncommon among the practices assessed. Greater attention needs to be paid to CV disease risk factor screening in patients with lupus.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12610807

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  35 in total

Review 1.  [Cardiovascular manifestations in inflammatory rheumatic diseases].

Authors:  U Lange; J Strunk
Journal:  Z Rheumatol       Date:  2005-02       Impact factor: 1.372

2.  Anti-CD3 antibody therapy attenuates the progression of hypertension in female mice with systemic lupus erythematosus.

Authors:  Keisa W Mathis; Erin B Taylor; Michael J Ryan
Journal:  Pharmacol Res       Date:  2017-04-08       Impact factor: 7.658

Review 3.  The role of preventive cardiology in systemic lupus erythematosus.

Authors:  Jennifer Rae Elliott; Susan Manzi; Daniel Edmundowicz
Journal:  Curr Rheumatol Rep       Date:  2007-05       Impact factor: 4.592

4.  Brief Report: Trends in Hospitalizations Due to Acute Coronary Syndromes and Stroke in Patients With Systemic Lupus Erythematosus, 1996 to 2012.

Authors:  Maria G Tektonidou; Zhong Wang; Michael M Ward
Journal:  Arthritis Rheumatol       Date:  2016-11       Impact factor: 10.995

5.  Cardiovascular Disease Prevention Counseling Program for Systemic Lupus Erythematosus Patients.

Authors:  Cécile M Yelnik; Monica Richey; Virginia Haiduc; Sotiria Everett; Meng Zhang; Doruk Erkan
Journal:  Arthritis Care Res (Hoboken)       Date:  2017-06-26       Impact factor: 4.794

6.  Human recombinant relaxin-2 does not attenuate hypertension or renal injury but exacerbates vascular dysfunction in a female mouse model of SLE.

Authors:  Victoria L Wolf; Taylor L Phillips; Erin B Taylor; Jennifer M Sasser; Michael J Ryan
Journal:  Am J Physiol Heart Circ Physiol       Date:  2019-05-24       Impact factor: 4.733

Review 7.  Understanding mechanisms of hypertension in systemic lupus erythematosus.

Authors:  Erin B Taylor; Michael J Ryan
Journal:  Ther Adv Cardiovasc Dis       Date:  2016-03-15

8.  Blood pressure in a hypertensive mouse model of SLE is not salt-sensitive.

Authors:  Keisa W Mathis; Marcia Venegas-Pont; Chester W Masterson; Katie L Wasson; Michael J Ryan
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2011-09-14       Impact factor: 3.619

9.  Von Willebrand factor, red cell fragmentation, and disease activity in systemic lupus erythematosus.

Authors:  Rodolfo V Curiel; Rajkumari Bhagati; Lakshmi Basavaraju; Delona Norton; James Katz; Elizabeth Haile; Arthur Weinstein
Journal:  HSS J       Date:  2008-07-01

10.  Temporal hemodynamic changes in a female mouse model of systemic lupus erythematosus.

Authors:  Elena L Dent; Erin B Taylor; Jennifer M Sasser; Michael J Ryan
Journal:  Am J Physiol Renal Physiol       Date:  2020-03-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.